# Cara Therapeutics, Inc. clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Cara Therapeutics, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Cara Therapeutics, Inc.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/cara-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 7, 2023 | NCT05978063 | Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica | Cara Therapeutics, Inc. | Phase 2/3 | Terminated | Pruritus, Notalgia Paresthetica | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05978063) |
| September 8, 2022 | NCT05533008 | CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients | Cara Therapeutics, Inc. | Phase 1 | Completed | Hemodialysis | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05533008) |
| May 24, 2022 | NCT05387707 | Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe... | Cara Therapeutics, Inc. | Phase 3 | Terminated | Pruritus, Atopic Dermatitis | 287 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05387707) |
| May 2, 2022 | NCT05356403 | CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With... | Cara Therapeutics, Inc. | Phase 3 | Terminated | Chronic Kidney Diseases, Pruritus | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05356403) |
| April 22, 2022 | NCT05342623 | A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus | Cara Therapeutics, Inc. | Phase 3 | Terminated | Chronic Kidney Diseases, Pruritus | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05342623) |
| September 2, 2021 | NCT05031546 | Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin | Cara Therapeutics, Inc. | Not applicable | Approved for marketing | Uremic Pruritus | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05031546) |
| January 13, 2021 | NCT04706975 | Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia... | Cara Therapeutics, Inc. | Phase 2 | Completed | Pruritus, Notalgia Paresthetica | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04706975) |
| July 15, 2019 | NCT04019574 | Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects | Cara Therapeutics, Inc. | Phase 1 | Completed | Healthy | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04019574) |
| July 12, 2019 | NCT04018027 | Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis | Cara Therapeutics, Inc. | Phase 2 | Completed | Pruritus, Atopic Dermatitis | 401 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04018027) |
| June 26, 2019 | NCT03998163 | CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | Cara Therapeutics, Inc. | Phase 3 | Completed | Uremic Pruritus | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03998163) |
| June 21, 2019 | NCT03995212 | Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and... | Cara Therapeutics, Inc. | Phase 2 | Terminated | Cholestatic Pruritus | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03995212) |
| May 13, 2019 | NCT03947970 | Study to Evaluate the Pharmacokinetics and Metabolism of \[14C\] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on... | Cara Therapeutics, Inc. | Phase 1 | Completed | Hemodialysis, Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03947970) |
| August 17, 2018 | NCT03636269 | CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | Cara Therapeutics, Inc. | Phase 3 | Completed | Uremic Pruritus | 473 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03636269) |
| August 6, 2018 | NCT03617536 | A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus | Cara Therapeutics, Inc. | Phase 2 | Completed | Chronic Kidney Diseases, Pruritus | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03617536) |
| February 6, 2018 | NCT03422653 | A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) | Cara Therapeutics, Inc. | Phase 3 | Completed | Uremic Pruritus | 378 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03422653) |
| September 13, 2017 | NCT03281538 | Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | Cara Therapeutics, Inc. | Phase 3 | Completed | Uremic Pruritus | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03281538) |
| October 25, 2016 | NCT02944448 | A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee | Cara Therapeutics, Inc. | Phase 2 | Completed | Osteoarthritis, Hip, Osteoarthritis, Knee, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases | 761 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02944448) |
| August 8, 2016 | NCT02858726 | Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | Cara Therapeutics, Inc. | Phase 2/3 | Completed | Uremic Pruritus | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02858726) |
| September 7, 2015 | NCT02542384 | A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery | Cara Therapeutics, Inc. | Phase 2/3 | Completed | Post Abdominal Surgery Pain | 451 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02542384) |
| August 14, 2015 | NCT02524197 | A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee | Cara Therapeutics, Inc. | Phase 2 | Completed | Osteoarthritis | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02524197) |
| September 3, 2014 | NCT02229929 | Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus | Cara Therapeutics, Inc. | Phase 2 | Completed | Pruritus, Uremic Pruritus | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02229929) |
| February 12, 2013 | NCT01789476 | A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery | Cara Therapeutics, Inc. | Phase 2 | Completed | Acute Pain | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01789476) |
| May 27, 2011 | NCT01361568 | Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery | Cara Therapeutics, Inc. | Phase 2 | Completed | Postoperative Pain | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01361568) |
| April 8, 2009 | NCT00877799 | Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery | Cara Therapeutics, Inc. | Phase 2 | Completed | Acute Pain | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00877799) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Terminated | 5 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pruritus | 14 |
| Renal Insufficiency, Chronic | 10 |
| Kidney Failure, Chronic | 9 |
| Pain | 4 |
| Acute Pain | 3 |
| Arthritis | 2 |
| Osteoarthritis | 2 |
| Dermatitis, Atopic | 2 |
| Eczema | 2 |
| Visceral Pain | 2 |
| Osteoarthritis, Hip | 1 |
| Osteoarthritis, Knee | 1 |
| Joint Diseases | 1 |
| Musculoskeletal Diseases | 1 |
| Rheumatic Diseases | 1 |
| Pain, Postoperative | 1 |
| Liver Cirrhosis, Biliary | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Fish and chips restaurants in the United States](https://specstream.ai/data/businesses/fish-and-chips-restaurants/united-states)
